Adagene Announces FDA Clearance Of IND For Phase 1b/2 Trial Of Anti-CTLA-4 Monoclonal Antibody ADG116 In Combination Therapy With Anti-PD-1 Antibody Pembrolizumab

by | Nov 29, 2021 | Extra Jobs | 0 comments

Submit a Comment Cancel reply

Your email address will not be published. Required fields are marked *

Comment *

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.